You are here

  • Home
  • Archive
  • Volume 104, Issue Suppl 6
  • 60 The ardvaarc study (altered rivaroxaban doses, vitamin-K anticoagulation & academic research consortium bleeding): real-world’ outcomes of patients who require anticoagulation following percutaneous coronary intervention (PCI)

Citation Tools

Article menu
Download PDFPDF
Interventional Cardiology
60 The ardvaarc study (altered rivaroxaban doses, vitamin-K anticoagulation & academic research consortium bleeding): real-world’ outcomes of patients who require anticoagulation following percutaneous coronary intervention (PCI)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Wa MLK, Khouri A, Whitfield M, et al
60 The ardvaarc study (altered rivaroxaban doses, vitamin-K anticoagulation & academic research consortium bleeding): real-world’ outcomes of patients who require anticoagulation following percutaneous coronary intervention (PCI)
Heart 2018;104:A53-A54.